Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:ALVR NASDAQ:MRKR NASDAQ:ONVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$3.46-9.4%$2.85$2.00▼$5.00$16.12M2.27.18 million shs164,851 shsALVRAlloVir$2.46+8.4%$2.62$7.96▼$24.15$12.41M0.6315,685 shs78,611 shsMRKRMarker Therapeutics$1.26+0.8%$1.50$0.95▼$5.95$14.25M1.45254,814 shs101,950 shsONVOOrganovo$3.94$1.56▼$21.96$3.47M1.13617,505 shs243,634 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos0.00%+8.81%+24.91%+31.06%+1.62%ALVRAlloVir0.00%-7.87%+1.65%-29.31%-85.60%MRKRMarker Therapeutics0.00%+5.88%-25.88%+11.50%-63.90%ONVOOrganovo0.00%0.00%0.00%0.00%-69.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos0.9113 of 5 stars0.03.00.00.02.31.70.6ALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AMRKRMarker Therapeutics4.011 of 5 stars3.82.00.03.93.30.00.6ONVOOrganovoN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/AALVRAlloVir 0.00N/AN/AN/AMRKRMarker Therapeutics 3.50Strong Buy$13.17944.97% UpsideONVOOrganovo 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$20K806.18N/AN/A$5.51 per share0.63ALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AMRKRMarker Therapeutics$6.59M2.16N/AN/A$1.73 per share0.73ONVOOrganovo$122K0.00N/AN/A$0.02 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$4.99N/A∞N/AN/A-108.25%-56.94%8/18/2025 (Estimated)ALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%N/AMRKRMarker Therapeutics-$10.73M-$1.37N/AN/AN/A-271.12%-108.20%-87.77%N/AONVOOrganovo-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%N/ALatest ONVO, MRKR, ALVR, and AIMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MRKRMarker Therapeutics-$0.55-$0.29+$0.26-$0.29$0.72 million$0.86 million8/13/2025Q2 2025AIMDAinosN/A-$0.99N/A-$0.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AALVRAlloVirN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.962.882.61ALVRAlloVirN/A86.7886.78MRKRMarker TherapeuticsN/A6.796.79ONVOOrganovoN/A0.721.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AALVRAlloVir66.05%MRKRMarker Therapeutics22.39%ONVOOrganovo8.23%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%ALVRAlloVir32.07%MRKRMarker Therapeutics7.80%ONVOOrganovo3.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos404.66 million4.17 millionNot OptionableALVRAlloVir1105.04 million3.43 millionOptionableMRKRMarker Therapeutics6011.31 million10.43 millionNot OptionableONVOOrganovo201.70 million14.79 millionOptionableONVO, MRKR, ALVR, and AIMD HeadlinesRecent News About These CompaniesDriven! The Onvo L60 Is China’s Best Tesla Model Y Killer to DateMay 18, 2025 | msn.comTwo new option listings and one option delisting on April 24thApril 25, 2025 | markets.businessinsider.comVivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ MarketApril 24, 2025 | globenewswire.comOrganovo announces VivoSim to carry forward 3D bioprinting, legacy techApril 23, 2025 | markets.businessinsider.comOrganovo Holdings, Inc. Announces Name Change to VivoSim Labs, Inc. and New Ticker Symbol "VIVS"April 23, 2025 | quiverquant.comQVivoSim to Carry Forward Organovo 3D BioprintingApril 23, 2025 | globenewswire.comOrganovo expects to meet requirements for continued listing on NasdaqApril 2, 2025 | markets.businessinsider.comOrganovo Holdings Expects to Meet Nasdaq Listing RequirementsApril 2, 2025 | tipranks.comOrganovo Provides Update on Cash and Nasdaq Continued Listing RequirementsApril 2, 2025 | financialpost.comFOrganovo Provides Update on Cash and Nasdaq Continued Listing RequirementsApril 2, 2025 | globenewswire.comOrganovo sees cash runway through the end of FY26March 28, 2025 | markets.businessinsider.comOrganovo, Inc.: Organovo Provides Business UpdateMarch 27, 2025 | finanznachrichten.deOrganovo Provides Business UpdateMarch 27, 2025 | financialpost.comFOrganovo Provides Business UpdateMarch 27, 2025 | globenewswire.comOrganovo, Inc.: Organovo Announces Close of the Sale of FXR Program to Eli Lilly and CompanyMarch 26, 2025 | finanznachrichten.deOrganovo closes sale of FXR program to Eli LillyMarch 25, 2025 | markets.businessinsider.comOrganovo Holdings, Inc. Completes Sale of FXR Program to Eli Lilly and CompanyMarch 25, 2025 | quiverquant.comQOrganovo Announces Close of the Sale of FXR Program to Eli Lilly and CompanyMarch 25, 2025 | globenewswire.comOrganovo Announces 1-for-12 Reverse Stock Split To Maintain Nasdaq ComplianceMarch 21, 2025 | nasdaq.comOrganovo trading halted, news pendingMarch 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONVO, MRKR, ALVR, and AIMD Company DescriptionsAinos NASDAQ:AIMD$3.46 -0.36 (-9.42%) As of 08/15/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.AlloVir NASDAQ:ALVR$2.46 +0.19 (+8.37%) As of 08/15/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Marker Therapeutics NASDAQ:MRKR$1.26 +0.01 (+0.80%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.26 0.00 (0.00%) As of 08/15/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Organovo NASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access